- Login
- Register & Subscribe
- Language: EN FR DE
Research & University News
GSK starts Phase 3 melanoma trials
Wednesday 30 May 2012
GlaxoSmithKline Plc has announced the start of two Phase 3 studies that will evaluate the effectiveness of a new combination therapy for the treatment of patients with BRAF-positive metastatic cutaneous melanoma. The studies will also look at safety.
Location
United Kingdom
Lundbeck reports on trial of AD drug
Tuesday 29 May 2012
H. Lundbeck A/S said that its experimental treatment for Alzheimer’s disease, Lu AE58054, met its primary endpoint in a Phase 2 proof-of-concept study of 278 patients with moderate disease already being treated with donepezil. Full data will be disclosed at upcoming medical meetings.
Location
Denmark
Ensemble and Genentech to collaborate on macrocyclic drugs
Tuesday 29 May 2012
Ensemble Therapeutics Corporation and Genentech (Roche) have entered into a collaboration to discover new drug candidates using the US company’s macrocyclic technology platform. Financial terms were not disclosed.
Location
United States
Karolinska and GE Healthcare to collaborate on cell therapy
Tuesday 29 May 2012
The Karolinska University Hospital and GE Healthcare Life Sciences have started a joint research collaboration to address some of the issues associated with the manufacture and development of new cell therapies. Financial terms weren’t given.
Location
Sweden
IMI launches €223.7 million antibiotic project
Friday 25 May 2012
The European Commission and the pharmaceutical industry have committed €223.7 million to research new antibiotic medicines in the first of several projects to be carried under the Innovative Medicines Initiative (IMI).
Location
Belgium
Nexavar lung cancer trial does not meet primary endpoint
Tuesday 22 May 2012
A Phase 3 trial of Nexavar (sorafenib) in patients with advanced, relapsed non-small cell lung cancer has failed to meet its primary endpoint of improving overall survival, according to Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc.
Location
United States
Lundbeck reports positive data for MDD drug
Monday 14 May 2012
H. Lundbeck A/S said that top-line results from three recently completed Phase 3 trials of its investigational drug for major depressive disorder, Lu AA21004, showed statistically significant reductions in depression symptoms in patients.
Location
Denmark
Roche stops dalcetrapib trial
Monday 7 May 2012
The Roche group has stopped a Phase 3 trial of dalcetrapib, a novel treatment for patients with dyslipidemia due to the lack of clinically meaningful efficacy. The decision was taken on the recommendation of the data and safety monitoring board.
Location
Switzerland
Novartis says new drug is better than old
Monday 7 May 2012
Novartis said that a Phase 3 trial of its new drug for acromegaly, pasireotide, is superior to the current standard of care for the disease. The current standard of care, Sandostatin (octreotide), is an older Novartis medicine.
Location
Switzerland
Probiodrug reports research finding
Friday 4 May 2012
New research has been published in Nature suggesting that the peptide pyroglutamate amyloid beta may play a crucial role in the initiation of Alzheimer’s disease. The research was conducted by scientists at Probiodrug AG and their academic partners.
Location
Germany
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013